Abstract TP188: Trends in Costs Associated With Endovascular and Surgical Treatments for Unruptured Intracranial Aneurysm Among Commercially Insured Patients

Abstract

Objectives: Limited studies have examined economic outcomes of endovascular coiling (EVC) and/ or surgical clipping (SC) for unruptured intracranial aneurysm (UIA) from a payer perspective. This study evaluated trends in payments for index admission and 365-day follow-up (including index admission) among UIA patients treated with EVC or SC. Methods: A retrospective analysis of Truven MarketScan® Commercial Claims and Encounters (CCAE) database was conducted. The study sample included patients aged ≥ 18 years with a diagnosis of UIA who underwent EVC or SC between 2011 and 2016 (index hospitalization). The following exclusion criteria were applied: patients with a history of subarachnoid hemorrhage (SAH) or EVC/SC treatment in 12 months baseline; concurrent diagnosis of SAH during index hospitalization or lack of continuous enrollment in 12 months baseline period. Using Mann-Kendall test, we examined trends in payments for index admission and 365-day all-cause healthcare utilization (medical services and prescription). All costs were adjusted to 2016 US dollar. Results: A total of 3,294 patients met the eligibility criteria. The mean age of patients was 52.53 years (SD= 8.64) and 76.56% were female. The proportions of patients treated with EVC (vs. SC) increased from 67.80% in 2011 to 75.84% in 2016 (p= 0.01). The average index admission cost was $54,853 and the mean 365-day follow-up cost was $89,398. Mean index admission cost was $52,163 in 2011 and $64,193 in 2016 (p= 0.19). However, mean 365-day all-cause follow-up costs increased from $87,741 in 2011 to $94,096 in 2016 (p= 0.04). Conclusions: The 365-day all-cause follow-up costs associated with endovascular and surgical treatment among UIA patients increased significantly over the study period. There is significant economic burden for UIA patients undergoing neurointerventional procedures.